Background: The economic impact of therapeutic non-adherence in chronic diseases has rarely been examined using qualitative standards for economic evaluation. This study illustrates the impact of non-adherence on the cost utility of renal transplantation versus haemodialysis from the societal...

There is growing consensus that a major obstacle to good outcomes among individuals with bipolar disorder (BPD) is premature discontinuation of medications. This review summarizes the current literature on prevalence and consequences of non-adherence in BPD populations, measurement of adherence,...

Objective: To assess the relationship between diabetic medication adherence, total healthcare costs, and utilization within patients with type 2 diabetes mellitus and concomitant diabetes and cardiovascular disease (CVD). Research design and methods: This study was a retrospective analysis of...

Heart failure (HF) is a major public health problem which is increasing in prevalence due to the aging of the population. Despite recent advances in the pharmacotherapy of HF, morbidity and mortality rates both remain high, owing in part to the presence of multiple medical, psychosocial,...

Relapse of schizophrenia due to poor medication adherence is a major preventable source of psychiatric morbidity. This has led to a burgeoning of interest in improving compliance based on a wide range of psychological approaches. One of the difficulties for health service providers is to...

Despite an abundance of literature that assesses medication compliance associated with specific diseases, its impact on patient outcomes remains poorly characterised, perhaps due to the complexity associated with its influence and measurement. Much of the previous research includes end-points...

A number of large randomized controlled trials (RCTs) have documented the effectiveness of HMG-CoA reductase inhibitor (`statin') therapy for both primary and secondary prevention of coronary heart disease. Current international guidelines, therefore, recommend the use of statin therapy in...

There are numerous studies examining the pharmacoeconomic impact of HMG-CoA reductase inhibitor (statin) therapy on healthcare costs and outcomes. A recently published review demonstrated that the cost-benefit of these agents depends primarily on the risk of developing a coronary event. That is,...

Background: Non-adherence to antihypertensive drugs is high, and the economic consequences of non-adherence may be substantial. The Medication Events Monitoring System (MEMS), which is a method to improve adherence, has been shown to be a useful tool for the management of adherence problems....

Objective: To assess associations between race/ethnicity and medication adherence, and the potential modifying effects of weight category (normal, overweight, obese) in a community-based sample. Study design and setting: We studied 1355 participants from the CARDIA (Coronary Artery Risk...